ALLO - Allogene Therapeutics up 7% following upgrade from Baird

• Baird has upgraded Allogene Therapeutics ( NASDAQ: ALLO ) to outperform from neutral.
• The firm has a price target of $12 (~107% upside based on Thursday's close).
• Analyst Jack Allen said that Allogene ( ALLO ) has differentiated itself from other allogeneic cell therapy developers in that its candidates have demonstrated positive durability results.
• He noted that in a late November R&D company showcase, data on the CD19 program, led by ALLO-501A, demonstrated that a significant number of large B cell lymphoma participants experienced a complete response.
• Allen added that allogenic cell therapies could serve a niche market for patients who cannot wait for an autologous therapy to be manufactured.
• Also, Allogene ( ALLO ) could become a takeout target if its "current suppressed valuation" continues.
• Read why Seeking Alpha contributor Avisol Capital Partners rates Allogene ( ALLO ) a hold.

For further details see: